Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Community Stories
DMD
DM1
Careers
Investors
News
Contact
CONNECT1 – EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping
Post navigation
Previous:
CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGNEDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping
Next:
CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 Skipping (Oral Presentation)
